Allergic bronchopulmonary aspergillosis in asthma: epidemiological, clinical and therapeutic issues.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder caused by immunologic reactions to antigens released by Aspergillus fumigatus, a ubiquitous fungi colonizing the tracheobronchial tree of asthmatic patients. The clinical presentation is usually poorly controlled asthma, recurrent pulmonary opacities and bronchiectasis. The prevalence of ABPA in asthma clinics may be as high as 13% with a global burden of almost 5 million patients. A. fumigatus-specific IgE level is the most sensitive test in diagnosis of ABPA, and all asthmatic patients should be routinely screened with A. fumigatus-specific IgE levels for early diagnosis. The goals of managing ABPA include control of asthma, prevention and treatment of acute exacerbations, and preventing the development or progression of bronchiectasis. Glucocorticoids are the treatment of choice with itraconazole reserved for those with recurrent exacerbations and glucocorticoid-dependent disease. There is a dire need for newer treatment approaches including oral antifungal agents and immunomodulatory therapy.

• Authors: Ritesh Agarwal, Arunaloke Chakrabarti
• Journal: Future microbiology (Future Microbiol) Vol. 8 Issue 11 Pg. 1463-74 (Nov 2013) ISSN: 1746-0921 [Electronic] England
• PMID: 24199804 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Glucocorticoids

Topics

• Antifungal Agents (therapeutic use)
• Aspergillosis, Allergic Bronchopulmonary (drug therapy, epidemiology, etiology, microbiology)
• Aspergillus fumigatus (drug effects, physiology)
• Asthma (complications)
• Glucocorticoids (therapeutic use)
• Humans